Compare AIR & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIR | KNSA |
|---|---|---|
| Founded | 1951 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.5B |
| IPO Year | 1994 | 2018 |
| Metric | AIR | KNSA |
|---|---|---|
| Price | $113.14 | $48.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $131.20 | $60.86 |
| AVG Volume (30 Days) | 312.7K | ★ 501.4K |
| Earning Date | 03-24-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | ★ 3.59 | 0.27 |
| Revenue | N/A | ★ $677,564,000.00 |
| Revenue This Year | $18.83 | $37.48 |
| Revenue Next Year | $10.93 | $17.87 |
| P/E Ratio | ★ $31.93 | $188.52 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $60.74 | $26.27 |
| 52 Week High | $127.21 | $59.87 |
| Indicator | AIR | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 52.34 | 36.64 |
| Support Level | $111.65 | $40.67 |
| Resistance Level | $121.05 | $49.57 |
| Average True Range (ATR) | 3.95 | 2.02 |
| MACD | 0.71 | -1.15 |
| Stochastic Oscillator | 65.95 | 3.18 |
AAR Corp is engaged in providing products and services to aviation, government and defense market. It operates in segments namely: The parts supply segment majorly consists of sales and leasing of USM and aftermarket distribution of new, OEM-supplied replacement parts; Repair & Engineering segment provides airframe maintenance, component repair, and landing gear overhaul services; Integrated Solutions segment consists of its fleet management and operations of customer-owned aircraft, customized performance-based supply chain logistics programs in support of the U.S. Department of Defense, flight hour component inventory; and The Expeditionary Services segment consists of products and services supporting the movement of equipment and personnel by the U.S. and foreign governments and NGOs.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.